Company profile
Candel Therapeutics, Inc.
NASDAQ: CADL · Healthcare · Biotechnology
#1033 of 1,422 Healthcare companies by revenue41st-percentile growth
EA Score
33DFH 37DQ 23GM —SS 50
v0.1 · 55/100 weight · provisional
↑ Altman-Z, market scale · ↓ operating margin, net margin
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$38.2M
Employees
55
as of 2026-08-11
Market cap
$769.3M
as of 2026-08-11
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$125.0k$125.0k2022
Net income-$38.2M-$38.2M2025
Operating income-$48.3M-$48.3M2025
Total assets$125.2M$125.2M2025
Liabilities$73.3M$73.3M2025
Equity$51.9M$51.9M2025
Revenue trend
FY2021 – FY2022 · USD
FY21
FY21
FY22
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Candel Therapeutics, Inc.’s revenue?
Candel Therapeutics, Inc. booked $125.0k in FY2022 revenue, growing 0.0% year over year — about the middle of the pack among Healthcare companies we track, at a -30545.6% net margin.
Peers · Healthcare
Serina Therapeutics, Inc.41DVentriPoint Diagnostics Ltd.31DPanamera Holdings Corporation31DAinos, Inc.41DAdvanced BioMedical Technologies Inc.——AI/ML Innovations Inc.——Neighbors
Norfolk →Key facts
CEOPaul-Peter Tak
SectorHealthcare
IndustryBiotechnology
HeadquartersNeedham, MA
ExchangeNASDAQ: CADL
Employees55
IPO date2021-07-27
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.